Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

AbbVie Inc (NYSE: ABBV) is a better long-term investment than peer Bristol-Myers Squibb Co (NYSE: BMY) even though the latter just secured FDA approval for its Psoriasis pill, says Mohit Bansal. He's a Managing Director at Wells Fargo.

Bristol-Myers versus AbbVie stock: Expert picks a side

NEARLY 20,000 PEOPLE RESPONDED TO AN OPEN CASTING CALL FOR A CHANCE TO BE FEATURED IN THE UPCOMING CAMPAIGN FOR THE NUMBER ONE SELLING PRODUCT OF ITS KIND IRVINE, Calif. , Sept. 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX® Cosmetic 'See Yourself' campaign.

Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories

Abbott Labs

Gilead Sciences

These stocks offer more than just dividends.

3 Unstoppable Dividend Stocks to Buy in September

This pair of Midwestern companies have outperformed in recent years, and their futures look brighter than ever.

2 Dividend Aristocrats to Buy for Passive Income That Could Outperform the Market

Amcor Plc

Air Products and Chemicals

Franklin Resources

Caterpillar

Federal Realty Investment Trust

Leggett & Platt

Medtronic

Realty Income Corp

Stanley Black & Decker

T. Rowe Price Group

V.F.

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 65 Aristocrats screened as of September 8, 2022 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 16.54%-36.34% topped by VFC & SWK.

4 S&P 500 Dividend Aristocrat Dogs To Buy, 1 To Watch

Amgen

Biogen

Pfizer

Is now a good time to add these biotech stocks to your watchlist?

Best Stocks To Buy Now? 4 Biotech Stocks In Focus

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis1 - Ongoing treatment with SKYRIZI demonstrated consistent long-term efficacy in psoriatic arthritis with similar rates of improvement in skin (PASI 90) and joint (ACR, enthesitis, dactylitis) symptoms at week 100 as those reported at week 521 - No new safety signals were observed through 100 weeks1-4 NORTH CHICAGO, Ill. , Sept. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in adult patients with active psoriatic arthritis.

New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100

Crown Castle International

Costco

Chevron

Goldman Sachs

PepsiCo

Waste Management

Starting the session following Labor Day weekend in the red, it's clear that even so-called S&P 500 stocks to buy are feeling the heat. Toward the end of August, Federal Reserve chair Jerome Powell presented a less-than-encouraging picture for future monetary policy.

7 S&P 500 Stocks to Buy With Superior Fundamentals

MEASURE-AD was a real-world study of moderate to severe atopic dermatitis patients across 28 countries designed to assess the multidimensional burdens that diagnosed patients face1-3 Additional findings show that lower clinical burden and work impairment had a positive association with quality of life and lower disease severity scores1 Atopic dermatitis, also known as eczema, impacts up to an estimated 10 percent of adults and 25 percent of children globally and causes significant physical, psychological and economic impact4-7 NORTH CHICAGO, Ill. , Sept. 8, 2022 /PRNewswire/ -- An analysis from AbbVie's (NYSE: ABBV) three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis (an immune-mediated skin disease) who are not receiving systemic therapy had greater clinical, psychosocial and economic burdens compared to those receiving systemic therapy.1 A separate analysis from the MEASURE-AD study demonstrated that better quality of life – as measured by Dermatology Life Quality Index (DLQI) scores – and lower disease severity scores were associated with lower clinical burden and work impairment.2 Results from the MEASURE-AD subanalyses were featured at the 31st European Academy of Dermatology and Venereology (EADV) Hybrid Congress onsite in Milan and online from September 7-10 as a poster and an oral presentation.

New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients

--Results from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine will be showcased as an oral presentation --Breadth of research underscores AbbVie's leadership and commitment to people living with migraine NORTH CHICAGO, Ill. , Sept. 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.

AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022

JUVÉDERM® Collection of Fillers Continues Position as the World's Number One Chosen Dermal Filler Collection IRVINE, Calif. , Sept. 7, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its manufacturing facility in France has reached the milestone of producing and shipping 100 million syringes of JUVÉDERM® products globally.

Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®

Historically, September tends to be the worst month for the benchmark S&P 500 index. Still, the following two mega-cap names, according to experts, are worth owning here.

Two dividend stocks worth owning for a tough September

Lowe's

These companies don't just have impressive dividend track records.

3 Dividend Aristocrats to Buy That Could Beat the Market Over the Next 10 Years

Applied Materials

ASML Hld

Broadcom

Comcast

Home Depot

KLA-Tencor

Lam Research

Vail Resorts

Tractor Supply

These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio.

10 Best Dividend Stocks to Buy Now in September

Johnson & Johnson

One word describes these three stocks and their dividends -- solid.

3 Great Dividend Stocks to Buy in September

Merck

There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer better returns than MRK stock in the next three years.

Is Humira Maker A Better Bet Over Merck Stock?

Magellan Midstream Partners

Yield is not the be-all and end-all when picking out the best dividend stocks, especially in a volatile market like

Top 2 dividend shares to navigate stock market in H2, 2022

CVS Health

Buying these stocks now could lead to dividend payments that grow for the rest of your life.

3 Dividend Stocks to Buy in September for Passive Income Generation

Powerful, Effective, Targeted Topical Treatment Formulated to Prevent and Address Visible Signs of Body Skin Aging IRVINE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica ® Firm & Tone Lotion for Body, the first product from the professional-grade skincare line formulated to prevent and address visible signs of body skin aging for a toned look.1 It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of body skin firmness and tone, and improve the look of sagging skin.1 "The skin on the body represents 95% of our skin.

SkinMedica® Launches Firm & Tone Lotion for Body

-- Report is aimed at helping practitioners and the industry prepare for the future by supporting the evolving needs of patients -- -- North American medical aesthetic market expected to grow more than 10 percent annually through 2026* --    -- Built on robust research and analysis of global social listening data, global aesthetics practitioners, academic studies and Allergan Aesthetics proprietary global research into thousands of consumer attitudes1 -- IRVINE, Calif. , Aug. 30, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, and a global leader in medical aesthetics treatments, today announces the U.S. publication of 'The Future of Aesthetics' global trends report, developed to understand what is shaping the aesthetics industry of tomorrow.

Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report

Eli Lilly

The stock market rally ran into the harsh reality last Friday that any interest rate pivot by the Federal Reserve may not come until 2024.

8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends

Enterprise Products Partners

Flowers Foods

Gaming and Leisure Properties

Huntington Bancshares

JPMorgan Chase & Co

Kinder Morgan

LyondellBasell Industries

M.D.C. Holdings

Altria

Medical Properties Trust

Last-year, May-August, 2021, Kiplinger-Today listed eight sets of stocks sorted as: best-buys for 2021, infrastructure-plays, value, growth, small-cap, high-yield, housing-bets, and cash-flow-gushers. Those eight "exceptional-dividend" articles revealed 86-equities, 76-paying-dividends. Kiplinger article-titles were, '21 Best Stocks to Buy'; '14 Best Infrastructure Stocks'; '16 Best Value; '10 Dividends-Growth'; '6 Small-Cap'; '10 High-Yield 4% or More;' '12 Housing; '10 Cash-Flow-Gushers.'

Buy 16 August Exceptional Dividend Dogs Now

News for AbbVie Stock (ABBV)